RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Michele Carbone to Animals

This is a "connection" page, showing publications Michele Carbone has written about Animals.
Connection Strength

0.863
  1. Novelli F, Bononi A, Wang Q, Bai F, Patergnani S, Kricek F, Haglund E, Suarez JS, Tanji M, Xu R, Takanishi Y, Minaai M, Pastorino S, Morris P, Sakamoto G, Pass HI, Barbour H, Gaudino G, Giorgi C, Pinton P, Onuchic JN, Yang H, Carbone M. BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene ? environment interaction with asbestos. Proc Natl Acad Sci U S A. 2021 11 30; 118(48).
    View in: PubMed
    Score: 0.063
  2. Bononi A, Goto K, Ak G, Yoshikawa Y, Emi M, Pastorino S, Carparelli L, Ferro A, Nasu M, Kim JH, Suarez JS, Xu R, Tanji M, Takinishi Y, Minaai M, Novelli F, Pagano I, Gaudino G, Pass HI, Groden J, Grzymski JJ, Metintas M, Akarsu M, Morrow B, Hassan R, Yang H, Carbone M. Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma. Proc Natl Acad Sci U S A. 2020 12 29; 117(52):33466-33473.
    View in: PubMed
    Score: 0.059
  3. Carbone M, Arron ST, Beutler B, Bononi A, Cavenee W, Cleaver JE, Croce CM, D'Andrea A, Foulkes WD, Gaudino G, Groden JL, Henske EP, Hickson ID, Hwang PM, Kolodner RD, Mak TW, Malkin D, Monnat RJ, Novelli F, Pass HI, Petrini JH, Schmidt LS, Yang H. Tumour predisposition and cancer syndromes as models to study gene-environment interactions. Nat Rev Cancer. 2020 09; 20(9):533-549.
    View in: PubMed
    Score: 0.057
  4. Carbone M, Melino G. Stearoyl CoA Desaturase Regulates Ferroptosis in Ovarian Cancer Offering New Therapeutic Perspectives. Cancer Res. 2019 Oct 15; 79(20):5149-5150.
    View in: PubMed
    Score: 0.054
  5. Napolitano A, Carbone M. Malignant Mesothelioma: Time to Translate? Trends Cancer. 2016 09; 2(9):467-474.
    View in: PubMed
    Score: 0.044
  6. Qi F, Okimoto G, Jube S, Napolitano A, Pass HI, Laczko R, Demay RM, Khan G, Tiirikainen M, Rinaudo C, Croce A, Yang H, Gaudino G, Carbone M. Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-a signaling. Am J Pathol. 2013 Nov; 183(5):1654-66.
    View in: PubMed
    Score: 0.036
  7. Bertino P, Panigada M, Soprana E, Bianchi V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann PR, Siccardi A, Carbone M. Fowlpox-based survivin vaccination for malignant mesothelioma therapy. Int J Cancer. 2013 Aug 01; 133(3):612-23.
    View in: PubMed
    Score: 0.034
  8. Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res. 2012 Oct 01; 18(19):5352-63.
    View in: PubMed
    Score: 0.033
  9. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI, Bianchi ME, Carbone M. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12611-6.
    View in: PubMed
    Score: 0.028
  10. Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med. 2008 Jul; 14(4):316-21.
    View in: PubMed
    Score: 0.025
  11. Bocchetta M, Eliasz S, De Marco MA, Rudzinski J, Zhang L, Carbone M. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res. 2008 Feb 15; 68(4):1022-9.
    View in: PubMed
    Score: 0.024
  12. Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, Vacek P, Ramos-Nino M, Mossman BT, Pass HI, Carbone M. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci U S A. 2006 Sep 19; 103(38):14128-33.
    View in: PubMed
    Score: 0.022
  13. Kroczynska B, Carbone M. Cross reactivity between many anti-human antibodies for their hamster homologs provide the tools to study the signal transduction pathway activated by asbestos and SV40 in the malignant mesothelioma model. Mol Carcinog. 2006 Jul; 45(7):537-42.
    View in: PubMed
    Score: 0.022
  14. Carbone M, Bedrossian CW. The pathogenesis of mesothelioma. Semin Diagn Pathol. 2006 Feb; 23(1):56-60.
    View in: PubMed
    Score: 0.021
  15. Carbone M, Pass HI. Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition. J Thorac Oncol. 2006 Feb; 1(2):169-71.
    View in: PubMed
    Score: 0.021
  16. Cutrone R, Lednicky J, Dunn G, Rizzo P, Bocchetta M, Chumakov K, Minor P, Carbone M. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res. 2005 Nov 15; 65(22):10273-9.
    View in: PubMed
    Score: 0.021
  17. Carbone M, Pass HI. Multistep and multifactorial carcinogenesis: when does a contributing factor become a carcinogen? Semin Cancer Biol. 2004 Dec; 14(6):399-405.
    View in: PubMed
    Score: 0.019
  18. Carbone M, Rdzanek MA. Pathogenesis of malignant mesothelioma. Clin Lung Cancer. 2004 Apr; 5 Suppl 2:S46-50.
    View in: PubMed
    Score: 0.018
  19. Carbone M, Burck C, Rdzanek M, Rudzinski J, Cutrone R, Bocchetta M. Different susceptibility of human mesothelial cells to polyomavirus infection and malignant transformation. Cancer Res. 2003 Oct 01; 63(19):6125-9.
    View in: PubMed
    Score: 0.018
  20. Suarez JS, Novelli F, Goto K, Ehara M, Steele M, Kim JH, Zolondick AA, Xue J, Xu R, Saito M, Pastorino S, Minaai M, Takanishi Y, Emi M, Pagano I, Wakeham A, Berger T, Pass HI, Gaudino G, Mak TW, Carbone M, Yang H. HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma. Proc Natl Acad Sci U S A. 2023 09 26; 120(39):e2307999120.
    View in: PubMed
    Score: 0.018
  21. Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Aqeilan RI, Arama E, Baehrecke EH, Balachandran S, Bano D, Barlev NA, Bartek J, Bazan NG, Becker C, Bernassola F, Bertrand MJM, Bianchi ME, Blagosklonny MV, Blander JM, Blandino G, Blomgren K, Borner C, Bortner CD, Bove P, Boya P, Brenner C, Broz P, Brunner T, Damgaard RB, Calin GA, Campanella M, Candi E, Carbone M, Carmona-Gutierrez D, Cecconi F, Chan FK, Chen GQ, Chen Q, Chen YH, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Ciliberto G, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Daugaard M, Dawson TM, Dawson VL, De Maria R, De Strooper B, Debatin KM, Deberardinis RJ, Degterev A, Del Sal G, Deshmukh M, Di Virgilio F, Diederich M, Dixon SJ, Dynlacht BD, El-Deiry WS, Elrod JW, Engeland K, Fimia GM, Galassi C, Ganini C, Garcia-Saez AJ, Garg AD, Garrido C, Gavathiotis E, Gerlic M, Ghosh S, Green DR, Greene LA, Gronemeyer H, H?cker G, Hajn?czky G, Hardwick JM, Haupt Y, He S, Heery DM, Hengartner MO, Hetz C, Hildeman DA, Ichijo H, Inoue S, J??ttel? M, Janic A, Joseph B, Jost PJ, Kanneganti TD, Karin M, Kashkar H, Kaufmann T, Kelly GL, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Kluck R, Krysko DV, Kulms D, Kumar S, Lavandero S, Lavrik IN, Lemasters JJ, Liccardi G, Linkermann A, Lipton SA, Lockshin RA, L?pez-Ot?n C, Luedde T, MacFarlane M, Madeo F, Malorni W, Manic G, Mantovani R, Marchi S, Marine JC, Martin SJ, Martinou JC, Mastroberardino PG, Medema JP, Mehlen P, Meier P, Melino G, Melino S, Miao EA, Moll UM, Mu?oz-Pinedo C, Murphy DJ, Niklison-Chirou MV, Novelli F, N??ez G, Oberst A, Ofengeim D, Opferman JT, Oren M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pentimalli F, Pereira DM, Pervaiz S, Peter ME, Pinton P, Porta G, Prehn JHM, Puthalakath H, Rabinovich GA, Rajalingam K, Ravichandran KS, Rehm M, Ricci JE, Rizzuto R, Robinson N, Rodrigues CMP, Rotblat B, Rothlin CV, Rubinsztein DC, Rudel T, Rufini A, Ryan KM, Sarosiek KA, Sawa A, Sayan E, Schroder K, Scorrano L, Sesti F, Shao F, Shi Y, Sica GS, Silke J, Simon HU, Sistigu A, Stephanou A, Stockwell BR, Strapazzon F, Strasser A, Sun L, Sun E, Sun Q, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Troy CM, Turk B, Urbano N, Vandenabeele P, Vanden Berghe T, Vander Heiden MG, Vanderluit JL, Verkhratsky A, Villunger A, von Karstedt S, Voss AK, Vousden KH, Vucic D, Vuri D, Wagner EF, Walczak H, Wallach D, Wang R, Wang Y, Weber A, Wood W, Yamazaki T, Yang HT, Zakeri Z, Zawacka-Pankau JE, Zhang L, Zhang H, Zhivotovsky B, Zhou W, Piacentini M, Kroemer G, Galluzzi L. Apoptotic cell death in disease-Current understanding of the NCCD 2023. Cell Death Differ. 2023 05; 30(5):1097-1154.
    View in: PubMed
    Score: 0.017
  22. Gazdar AF, Butel JS, Carbone M. SV40 and human tumours: myth, association or causality? Nat Rev Cancer. 2002 Dec; 2(12):957-64.
    View in: PubMed
    Score: 0.017
  23. Powers A, Carbone M. The role of environmental carcinogens, viruses and genetic predisposition in the pathogenesis of mesothelioma. Cancer Biol Ther. 2002 Jul-Aug; 1(4):348-53.
    View in: PubMed
    Score: 0.016
  24. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002 Feb; 29(1):2-17.
    View in: PubMed
    Score: 0.016
  25. Xue J, Suarez JS, Minaai M, Li S, Gaudino G, Pass HI, Carbone M, Yang H. HMGB1 as a therapeutic target in disease. J Cell Physiol. 2021 05; 236(5):3406-3419.
    View in: PubMed
    Score: 0.015
  26. Xue J, Patergnani S, Giorgi C, Suarez J, Goto K, Bononi A, Tanji M, Novelli F, Pastorino S, Xu R, Caroccia N, Dogan AU, Pass HI, Tognon M, Pinton P, Gaudino G, Mak TW, Carbone M, Yang H. Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. Proc Natl Acad Sci U S A. 2020 10 13; 117(41):25543-25552.
    View in: PubMed
    Score: 0.014
  27. Daou S, Barbour H, Ahmed O, Masclef L, Baril C, Sen Nkwe N, Tchelougou D, Uriarte M, Bonneil E, Ceccarelli D, Mashtalir N, Tanji M, Masson JY, Thibault P, Sicheri F, Yang H, Carbone M, Therrien M, Affar EB. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1. Nat Commun. 2018 10 22; 9(1):4385.
    View in: PubMed
    Score: 0.013
  28. Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, Saad-Jube ZS, Napolitano A, Pagano I, Negi VS, Bianchi ME, Morris P, Pass HI, Gaudino G, Carbone M, Yang H. HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget. 2017 Apr 04; 8(14):22649-22661.
    View in: PubMed
    Score: 0.011
  29. Szymiczek A, Pastorino S, Larson D, Tanji M, Pellegrini L, Xue J, Li S, Giorgi C, Pinton P, Takinishi Y, Pass HI, Furuya H, Gaudino G, Napolitano A, Carbone M, Yang H. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. J Transl Med. 2017 03 15; 15(1):58.
    View in: PubMed
    Score: 0.011
  30. Larson D, Powers A, Ambrosi JP, Tanji M, Napolitano A, Flores EG, Baumann F, Pellegrini L, Jennings CJ, Buck BJ, McLaurin BT, Merkler D, Robinson C, Morris P, Dogan M, Dogan AU, Pass HI, Pastorino S, Carbone M, Yang H. Investigating palygorskite's role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicity. J Toxicol Environ Health B Crit Rev. 2016; 19(5-6):213-230.
    View in: PubMed
    Score: 0.010
  31. Rose AH, Bertino P, Hoffmann FW, Gaudino G, Carbone M, Hoffmann PR. Increasing dietary selenium elevates reducing capacity and ERK activation associated with accelerated progression of select mesothelioma tumors. Am J Pathol. 2014 Apr; 184(4):1041-1049.
    View in: PubMed
    Score: 0.009
  32. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M, Yang H. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012 Jul 01; 72(13):3290-301.
    View in: PubMed
    Score: 0.008
  33. Qi F, Carbone M, Yang H, Gaudino G. Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Rev Respir Med. 2011 Oct; 5(5):683-97.
    View in: PubMed
    Score: 0.008
  34. Altomare DA, Menges CW, Xu J, Pei J, Zhang L, Tadevosyan A, Neumann-Domer E, Liu Z, Carbone M, Chudoba I, Klein-Szanto AJ, Testa JR. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One. 2011 Apr 19; 6(4):e18828.
    View in: PubMed
    Score: 0.008
  35. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ, Pass HI, Carbone M, Testa JR, Heintz NH, Mossman BT. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer. 2011 Sep 01; 129(5):1075-86.
    View in: PubMed
    Score: 0.007
  36. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR, Mossman BT. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer. 2010 Dec 15; 9:314.
    View in: PubMed
    Score: 0.007
  37. Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA, Beuschel SL, Steinbacher JL, Butnor KJ, Ramos-Ni?o ME, Shukla A, James TA, Weiss DJ, Taatjes DJ, Pass HI, Carbone M, Landry CC, Mossman BT. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int J Cancer. 2011 Jul 01; 129(1):233-44.
    View in: PubMed
    Score: 0.007
  38. Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, Testa JR, Pass HI, Carbone M, Steele C, Mossman BT. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci. 2010 Aug; 1203:7-14.
    View in: PubMed
    Score: 0.007
  39. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. Cancer and inflammation: promise for biologic therapy. J Immunother. 2010 May; 33(4):335-51.
    View in: PubMed
    Score: 0.007
  40. Altomare DA, Menges CW, Pei J, Zhang L, Skele-Stump KL, Carbone M, Kane AB, Testa JR. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc Natl Acad Sci U S A. 2009 Mar 03; 106(9):3420-5.
    View in: PubMed
    Score: 0.006
  41. Beck AK, Pass HI, Carbone M, Yang H. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. Future Oncol. 2008 Jun; 4(3):341-9.
    View in: PubMed
    Score: 0.006
  42. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, Mossman BT. Cellular and molecular parameters of mesothelioma. J Cell Biochem. 2006 Jul 01; 98(4):723-34.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support